Evidence map›Paper›PMID 40745869›Full record

ArticleGut microbes2025

Pyruvate-GPR31 axis induces LysoDC dendrite protrusion to M-cell pockets for effective immune responses.

Katsuhiro Nakanishi, Takayuki Ajiro, Kaito Yukishima, Yuki Tsukamoto, Junichi Kikuta, Shinichiro Sawa, Michio Tomura, Nozomi Kinoshita, Wataru Shimanuki, Akio Suzuki and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Katsuhiro NakanishiLaboratory of Microbiology and Immunology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Takayuki AjiroLaboratory of Microbiology and Immunology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Kaito YukishimaLaboratory of Microbiology and Immunology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Yuki TsukamotoLaboratory of Microbiology and Immunology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Junichi KikutaDivision of Immunology, Department of Future Medical Sciences, Graduate School of Medicine, Kobe University, Hyogo, Japan.
Shinichiro SawaDivision of Mucosal Immunology, Research Center for Systems Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
Michio TomuraLaboratory of Immunology, Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan.
Nozomi KinoshitaLaboratory of Microbiology and Immunology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Wataru ShimanukiLaboratory of Microbiology and Immunology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Akio SuzukiDivision of Immunology, Department of Future Medical Sciences, Graduate School of Medicine, Kobe University, Hyogo, Japan.
Shun AraiLaboratory of Microbiology and Immunology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Kazuki MaeshimaLaboratory of Microbiology and Immunology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Takumi IchisawaLaboratory of Microbiology and Immunology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Tomoya KatakaiDepartment of Immunology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Haruko HayasakaDepartment of Life Science, Faculty of Science & Engineering, Kindai University, Osaka, Japan.
Masaru IshiiDepartment of Immunology and Cell Biology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Eiji UmemotoLaboratory of Microbiology and Immunology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.ORCID 0000-0002-8255-7149

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peyer's patches (PPs) are sites of antigen entry and immunoinduction in the small intestine. In PPs, pathogens are transferred through microfold (M) cells; however, the mechanisms of antigen capture by mononuclear phagocytes beneath M cells remain unclear. Here, we demonstrate that bacterial metabolite pyruvate acted on lysozyme-expressing dendritic cells (LysoDCs), a monocyte-derived phagocyte subset, and induced protrusion of dendrites particularly with "balloon" shapes into basolateral M-cell pockets via its receptor, G-protein coupled receptor 31 (GPR31). Pyruvate administration in wild-type but not

Indexed as

Dendritic CellsPeyer's PatchesPyruvic AcidReceptors, G-Protein-CoupledAnimalsAntigen PresentationListeria monocytogenesListeriosisMiceMice, Inbred C57BLMice, KnockoutMuramidaseSignal TransductionFfar2 protein, mouseMuramidasePyruvic AcidReceptors, G-Protein-Coupledcommensal metaboliteGPCR: dendritic cellListeria monocytogenesPeyer’s patch

Identifiers

PMID40745869
PMCPMC12320816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.